Literature DB >> 17129358

Up-regulation of a BCL9-related beta-catenin-binding protein, B9L, in different stages of sporadic colorectal adenoma.

Ichiro Sakamoto1, Susumu Ohwada, Hiroyuki Toya, Nozomi Togo, Kenji Kashiwabara, Tetsunari Oyama, Takashi Nakajima, Hideaki Ito, Shungo Adachi, Takafumi Jigami, Tetsu Akiyama.   

Abstract

Aberrant activation of Wnt signaling is a critical event in the development of human colorectal tumors. The aim of this study was to elucidate the role of B9L and its association with beta-catenin in each stage of the adenoma-carcinoma sequence of human colorectal tumorigenesis. We investigated the expression levels of B9L in sporadic colorectal adenomas and carcinomas, categorized according to the Vienna classification, using real-time quantitative polymerase chain reaction (RTQ-PCR) and immunohistochemical analysis. B9L was expressed in the nuclei of non-neoplastic colonic mucosa cells and was overexpressed in the nuclei of neoplasias and invasive carcinoma cells. Immunoreactivity to B9L protein was correlated with the progressive grades of colorectal neoplasias, as was the expression of B9L mRNA. A high level of immunoreactivity to nuclear B9L was present in 27% of low-grade neoplasias and in more than 50% of high-grade neoplasias and invasive carcinomas, whereas a high level of nuclear B9L immunoreactivity was not observed in any of the non-neoplastic mucosa samples. The expression of B9L was dramatically increased in low-grade neoplasias compared with that in non-neoplastic mucosa. B9L may play an important role in tumorigenesis induced by aberrant activation of Wnt signaling and may act as a key protein in the progressive dysplasia of adenoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17129358     DOI: 10.1111/j.1349-7006.2006.00363.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  8 in total

1.  Structure-Based Optimization of Small-Molecule Inhibitors for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.

Authors:  Min Zhang; Zhen Wang; Yongqiang Zhang; Wenxing Guo; Haitao Ji
Journal:  J Med Chem       Date:  2018-03-29       Impact factor: 7.446

2.  Cell-type-specific function of BCL9 involves a transcriptional activation domain that synergizes with beta-catenin.

Authors:  Claudio Sustmann; Henrik Flach; Hanna Ebert; Quinn Eastman; Rudolf Grosschedl
Journal:  Mol Cell Biol       Date:  2008-03-17       Impact factor: 4.272

3.  Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.

Authors:  Kohichi Takada; Di Zhu; Gregory H Bird; Kumar Sukhdeo; Jian-Jun Zhao; Mala Mani; Madeleine Lemieux; Daniel E Carrasco; Jeremy Ryan; David Horst; Mariateresa Fulciniti; Nikhil C Munshi; Wenqing Xu; Andrew L Kung; Ramesh A Shivdasani; Loren D Walensky; Daniel Ruben Carrasco
Journal:  Sci Transl Med       Date:  2012-08-22       Impact factor: 17.956

4.  BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.

Authors:  Mala Mani; Daniel E Carrasco; Yunyu Zhang; Kohichi Takada; Moshe E Gatt; Jui Dutta-Simmons; Hiroshi Ikeda; Felipe Diaz-Griffero; Victor Pena-Cruz; Monica Bertagnolli; Lois L Myeroff; Sanford D Markowitz; Kenneth C Anderson; Daniel R Carrasco
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

5.  The role of Pygo2 for Wnt/ß-catenin signaling activity during intestinal tumor initiation and progression.

Authors:  Suranand B Talla; Felix H Brembeck
Journal:  Oncotarget       Date:  2016-12-06

6.  Role of BCL9L in transforming growth factor-β (TGF-β)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer.

Authors:  Giuseppina Sannino; Nicole Armbruster; Mona Bodenhöfer; Ursula Haerle; Diana Behrens; Malte Buchholz; Ulrich Rothbauer; Bence Sipos; Christian Schmees
Journal:  Oncotarget       Date:  2016-11-08

7.  Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer.

Authors:  David M Gay; Rachel A Ridgway; Miryam Müller; Michael C Hodder; Ann Hedley; William Clark; Joshua D Leach; Rene Jackstadt; Colin Nixon; David J Huels; Andrew D Campbell; Thomas G Bird; Owen J Sansom
Journal:  Nat Commun       Date:  2019-02-13       Impact factor: 14.919

8.  The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells.

Authors:  Marc de la Roche; Jesper Worm; Mariann Bienz
Journal:  BMC Cancer       Date:  2008-07-15       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.